The aim of the present study was to compare quinagolide with cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in at-risk patients undergoing in-vitro fertilization (IVF) treatments and to compare the pregnancy rate, the tolerability and the complication rate of the two drugs.Study design
A randomized controlled trial.Patients and methods
A total of 112 patients undergoing IVF/intracytoplasmic sperm injection long luteal GnRH agonist procedure considered at risk of OHSS were randomized into two groups. Group I patients received quinagolide 75 µg and group II patients received cabergoline 0.5 mg for 8 days starting from the day of human chorionic gonadotrophin injection.Results
The total number of patients who developed OHSS in our study was similar in the two groups, with nine (16.1%) patients in the quinagolide group compared with 11 (19.6%) in the cabergoline group (P=0.81). However, the majority of these patients developed only mild OHSS comprising 55.6% in the quinagolide group and 63.6% in the cabergoline group. There was no statistical difference between the two groups regarding the incidence of early OHSS (P=0.77) or late OHSS (P=1.0). Severe/critical grades of OHSS occurred in only 3.6% of the cases in the quinagolide group and 1.8% of the cases in the cabergoline group, whereas the incidence of moderate OHSS was 3.6 and 5.4% in the quinagolide and the cabergoline groups, respectively. Quinagolide was responsible for significantly more nausea (P=0.03) and vomiting (P=0.009) than cabergoline, but there was no statistically significant difference between the two groups regarding other side effects.Conclusion
Quinagolide seems to be just as effective as cabergoline in the prevention of OHSS in at-risk patients undergoing IVF treatments.